RE:RE:Pricing failureI would suggest those very simple questions, addressed to whom you want to answer it, be submitted by all so that they have to answer them. It seems they look at all the questions, try to lump some together, and they don't seem to take a lot of questions from any one person. We've seen reports here from some where one of their 3 or 4 questions gets picked up.
So it behooves us all to place a few very simple questions like this, open-ended, so that they CAN explain these things best they can at this point. So please post questions next week and don't be shy. They are pretty good about it and I've usually gotten one or two in each quarter.
I see no reason why, at this point, they wouldn't discusss more around 1A and what they learned (safety, tests they need, PK data, nor how many patients rolled (we know it will be a pretty small number one way or the other given the final grouping was at most 6 and maybe half that), how enrollment has been, maybe the spread of cancers, new centers being signed up, etc... It wouldn't surprise me if the enrollment is going according to what the clinicians said and planned for, but it's not probably as quick as we are assuming. I say that because the reality is there are only 6 or so doctors on the trial, maybe a few of their colleagues, and given the advanced nature of each patient it sounds like there's at least 3 weeks of pre-trial testing that goes on. They probably can't sign-up more than a few over a month period and it will likely be staggered.
My guess is we hear the trial is going fine and 1b has between 6-10, maybe 12 total patients enrolled now and growing. That's probably fine and to be expected. Perhaps ask about what they hear from clinics on what they think new patients/month will be, dropouts, etc... Let's ask the questions that they can elaborate on and fill in all these blanks. These are hard trials for advanced patients so set expectations appropriately.
What we really need to hear is what have they learned so far about Sort1 as a target, getting around resistance, concentrating the drug, etc... Just the big ideas they've spoken about before. I'm sure they can't be conclusive around anything, but they should at least share some thoughts as a scientist might conclude or what questions they are asking themselves around what they've learned. They must try to start trying to dispel the horrible uncertainty if they can. IF they can't the share's just going to keep languishing and they'll lose even more shareholders and support. They need to start the education process in a far deeper way.
realitycheck4u wrote: Well, we do agree they are letting it plummet. Im not a fan of that 'strategy', and this is due to not saying anything, and when they do say something, there is holes in it. Did any ph1a patients move to ph1b? Yes? No? We do not know. Why did ph1a go so slowly? We don't know. Simple answers to very obvious questions are missing. Is there a reason for this? I would think maybe, but then the issue is, they should and could have explained this. Saying nothing is the issue.
Trogarzon wrote: It's a strategy... let it plummet until th1902 is priced as a total writoff and then put out your not so good news and praise your 80m in sales and you 10% line of credit... that's what is happening.